摘要
目的:为提高医院抗肿瘤药物处方专项点评质量提供参考。方法:用回顾与对比法,就《北京市医疗机构处方专项点评指南(试行)》(以下简称《指南》)的工作表与自拟工作表对比分析,同时对抗肿瘤药物门诊处方点评工作中存在的问题进行讨论。结果:《指南》工作表1、表2和自拟工作表1、表2用药指标存在差异,前者是药品品种数统计指标,后者是合理用药国际调研处方指标;存在问题有药品说明书[包括同种药品不同厂家说明书不一致、药品说明书与美国国立综合癌症网络(NCCN)指南不一致、药品说明书与《新编药物学》(16版)不一致],处方前记项目设置缺失,人为分解处方。结论:专项处方点评质量的提升亟待药品说明书和指导性规范的完善,以及医院信息系统的有力支撑。
OBJECTIVE: To provide reference for the quality improvement of antineoplastic drugs prescription special review. METHODS: By review and comparison method, the worksheet of Prescription Special Review Guide in Beijing Medical Institutions (trial) (hereinafter referred to as the Guidelines) was compared with self-made one. The problems about outpatient prescription review for antineoplastic drugs were also discussed. RESULTS: The worksheet 1 and worksheet 2 of Guidelines were different from self-made worksheet 1 and worksheet 2; the former was drug type statistics index, and the latter was international research prescription indicators of rational drug use. The problems included: the package inserts of the same kinds of drugs from different manufacturers were different from one another; the package inserts were inconsistent with NCCN guidelines; the package inserts were inconsistent with 16 version of New Pharmacology; item record setting before prescribing missed; the prescription was decomposed artificially. CONCLUSIONS: The quality improvement of special prescription review requires promoting package inserts and guide specifications urgently, and needs strong HIS support.
出处
《中国药房》
CAS
CSCD
2014年第42期4012-4015,共4页
China Pharmacy
关键词
抗肿瘤药物
处方
点评
Antineoplastic drugs
Prescription
Review